TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15165613
Drug: L-ornithine alpha-ketoglutarate
Normalized name: ornithine alpha-ketoglutarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine alpha-ketoglutarate (OKG) 10 g/d for 12 weeks
Study: 9357387
Drug: Chlorzoxazone 250
Normalized name: chlorzoxazone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorzoxazone 250 mg
Study: 9597564
Drug: Chlorzoxazone 750
Normalized name: chlorzoxazone 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorzoxazone 750 mg
Study: 7905550
Drug: More-effective treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: More-effective treatments (6 or more cycles of cyclophosphamide, methotrexate, fluorouracil and prednisone; with or without tamoxifen, or tamoxifen and prednisone alone)
Study: 7905550
Drug: Less-effective treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less-effective treatments (no treatment or a single cycle of chemotherapy)
Study: 3266449
Drug: Atropine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.01 mg/kg, intravenous)
Study: 31570429
Drug: Docetaxel treatment
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel treatment in variant carriers (ANO7 rs77559646)
Study: 28538831
Drug: Laryngeal Manual
Normalized name: LARYNGEAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laryngeal Manual Therapy (LMT)
Study: 23379785
Drug: High-bolus-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-bolus-dose tirofiban
Study: 21234549
Drug: AZD3783 (1-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3783 (1-40 mg oral doses)
Study: 18293707
Drug: Levocetirizine (LCZ)
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine (LCZ) 5 mg p.o.
Study: 12418583
Drug: telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telithromycin 800 mg once daily (qd) for 5 days
Study: 12418583
Drug: amoxicillin/clavulanate 500/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin/clavulanate 500/125 mg three times daily (tid) for 10 days
Study: 10080588
Drug: BR96‐doxorubicin conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BR96‐doxorubicin conjugate 700 mg/m2 IV over 24 hours
Study: 10080588
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 every 3 weeks
Study: 6998872
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg spironolactone
Study: 3621990
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg spironolactone
Study: 6998872
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg spironolactone
Study: 8916244
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (control group)
Study: 19563497
Drug: Continuous etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous etanercept therapy (25 mg SC BIW throughout 54 weeks)
Study: 19563497
Drug: Paused etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paused etanercept therapy (50 mg SC BIW for up to 12 weeks, then 25 mg BIW upon retreatment)
Study: 20492876
Drug: Continuous etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous etanercept therapy
Study: 19563497
Drug: Paused etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paused etanercept therapy
Study: 19563497
Drug: Both continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both continuous and paused etanercept treatment
Study: 9298132
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of 5-S-cysteinyldopa (5-S-CD)
Study: 9298132
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of 5-S-cysteinyldopa (5-S-CD) > 1,000 micrograms/day
Study: 9298132
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of 5-S-cysteinyldopa (5-S-CD) > 10,000 micrograms/day
Study: 9298132
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of 5-S-cysteinyldopa (5-S-CD) > 40,000 micrograms/day
Study: 2873379
Drug: Atenolol (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (5-10 mg iv immediately, followed by 100 mg/day orally for 7 days)
Study: 28616715
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab without anterior chamber paracentesis (group A)
Study: 28616715
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab with anterior chamber paracentesis (group B)
Study: 24080992
Drug: Zoledronic acid,
Normalized name: Zoledronic Acid, Anhydrous
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid, 4 mg, concurrently with the start of RT and then every six months for a total of 6 infusions (Arm 1)
Study: 21484236
Drug: Drug-related mood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-related mood induction
Study: 17143195
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day RRR-alpha-tocopherol
Study: 17143195
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day mixed tocopherols (60% gamma-tocopherol)
Study: 15138711
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion etoposide (days 1-6)
Study: 15138711
Drug: Bolus infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus infusion etoposide (over 10 h on day 7)
Study: 15138711
Drug: High-dose etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose etoposide (schedule-dependent)
Study: 11294082
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (specifics not available)
Study: 2087150
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline, 1 ml; i.v.)
Study: 240205
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg of lorazepam (orally) as a soporific and premedication
Study: 240205
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of lorazepam (orally) as a soporific and premedication
Study: 31269050
Drug: Treatment (home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (home visits, baby massage, and parenting program)
Study: 28689036
Drug: 3g edetate
Normalized name: EDETATE
DrugBank: Edetate sodium (DB13404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g edetate disodium-based infusion
Study: 28689036
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion of 500mL normal saline and 1.2% dextrose
Study: 21107585
Drug: Group-based treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based treatment (GT)
Study: 20957391
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment (IT)
Study: 22253980
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (BC) supplementation (60 g/day)
Study: 17427144
Drug: Influenza split
Normalized name: INFLUENZA SPLIT VIRUS '95-'96 VIL 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza split vaccine vaccination
Study: 11221809
Drug: Bedtime NPH
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime NPH insulin
Study: 8365296
Drug: Endotoxin (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin (7 mg/L)
Study: 8365296
Drug: Corn dust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn dust extract (0.08 ml/kg)
Study: 8365296
Drug: Soybean dust
Normalized name: Soybean dust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean dust extract (0.08 ml/kg)
Study: 25626910
Drug: Pars plana
Normalized name: Planatus occidentalis bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pars plana vitrectomy and 360° endolaser therapy
Study: 18412565
Drug: 8% Aluminium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% Aluminium Chlorohydrate (ACH) aqueous solution
Study: 18412565
Drug: 4%, 8%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4%, 8%, or 12% Aluminium Chlorohydrate (ACH) aqueous solution
Study: 12494207
Drug: Telmisartan (40‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40‐80 mg/day) for 24 weeks
Study: 7877305
Drug: Acadesine (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acadesine (low-dose and high-dose)
Study: 2212216
Drug: Metronidazole (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (250 mg, three times a day for one week) with scaling and root planing
Study: 355807
Drug: Sublingual milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual milk therapy
Study: 30359166
Drug: Adjunctive ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive ondansetron (8 mg/daily)
Study: 17579629
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus etoposide (CE); carboplatin AUC 5 IV on day 1 and etoposide 80 mg/m² IV on days 1-3, with G-CSF support for 4 courses.
Study: 17579629
Drug: Split doses
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split doses of cisplatin plus etoposide (SPE); cisplatin 25 mg/m² IV on days 1-3 and etoposide 80 mg/m² IV on days 1-3, with G-CSF support for 4 courses.
Study: 17579629
Drug: Split doses
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split doses of cisplatin plus etoposide (SPE)
Study: 16100444
Drug: FPG <5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG <5.0 mM/L (Group 1)
Study: 16100444
Drug: 5.6< or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.6< or =FPG <6.1 mM/L (Group 3)
Study: 16100444
Drug: 6.1< or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.1< or =FPG <7.0 mM/L (Group 4)
Study: 12085177
Drug: Marimastat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat (10 mg b.d.)
Study: 8903664
Drug: Mibefradil 150
Normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mibefradil 150 mg (acute study)
Study: 8903664
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR 240 mg (acute study)
Study: 8903664
Drug: Diltiazem 240
Normalized name: diltiazem 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 240 mg (acute study)
Study: 8903664
Drug: Mibefradil 100
Normalized name: mibefradil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 100 mg daily (chronic study)
Study: 8903664
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR 240 mg daily (chronic study)
Study: 2295997
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluoride mouthrinsing and fluoride tablets
Study: 2295997
Drug: Fluoride tablets
Normalized name: Sodium Fluoride Tablets
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride tablets (2.2 mg NaF daily)
Study: 2295997
Drug: Fluoride mouthrinsing
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride mouthrinsing (0.2% NaF solution weekly)
Study: 271588
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride jelly (four times continuous daily application)
Study: 271588
Drug: Aminofluoride jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminofluoride jelly (four times continuous daily application)
Study: 31068298
Drug: 1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/kg sufentanil combined with TAP block
Study: 31068298
Drug: 2 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg/kg sufentanil without TAP block
Study: 19707744
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (0.5 U/kg body weight)
Study: 19707744
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (0.5 U/kg body weight)
Study: 19707744
Drug: Both insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both insulin detemir and NPH insulin
Study: 18158020
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg BCG
Study: 18158020
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg BCG
Study: 18158020
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg BCG
Study: 12357261
Drug: Implantable cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter defibrillator and radiofrequency ablation in addition to antiarrhythmic drugs
Study: 10027342
Drug: Dexamethasone 20
Normalized name: dexamethasone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 20 mg with 5-HT3 antagonists
Study: 10027342
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg with 5-HT3 antagonists
Study: 10027342
Drug: Medium-dose dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medium-dose dexamethasone (8 mg) with 5-HT3 antagonists
Study: 6357659
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg taken at 1200
Study: 31905228
Drug: Typhax 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhax 0.5 μg
Study: 31905228
Drug: Typhax 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhax 2.5 μg
Study: 31905228
Drug: Typhax 10
Normalized name: TYPHA ANGUSTIFOLIA STEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhax 10 μg
Study: 31905228
Drug: Typhim Vi
Normalized name: Typhim VI
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhim Vi (25 μg)
Study: 27101283
Drug: IncobotulinumtoxinA injections
Normalized name: incobotulinumtoxinA Injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: IncobotulinumtoxinA injections at weeks 0, 16, and 32
Study: 27101283
Drug: IncobotulinumtoxinA injections
Normalized name: incobotulinumtoxinA Injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: IncobotulinumtoxinA injections
Study: 22198448
Drug: Asenapine 5
Normalized name: asenapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 5 or 10 mg
Study: 20958294
Drug: OnabotulinumtoxinA injection
Normalized name: onabotulinumtoxinA Injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA injection using the PREEMPT paradigm (both fixed and follow-the-pain sites)
Study: 30346346
Drug: OnabotulinumtoxinA injection
Normalized name: onabotulinumtoxinA Injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA injection
Study: 10605180
Drug: Cetrorelix 60
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix 60 mg
Study: 27062408
Drug: Fenofibrate 100
Normalized name: fenofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 100 mg QD
Study: 30193843
Drug: DHEA administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA administration (100 mg/day for 4 weeks)
Study: 27072219
Drug: Accelerated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiotherapy (ART) - 50 Gy in 25 fractions, six fractions weekly
Study: 27072219
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation (CRT) - 50 Gy in 25 fractions with weekly cisplatin
Study: 25566589
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine (15 mg, 3 mL)
Study: 25566589
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine (15 mg, 3 mL)
Study: 20447305
Drug: Agmatine sulfate
Normalized name: palmatine
DrugBank: Agmatine (DB08838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agmatine sulfate 2.670 g/day for 14 days
Study: 18797833
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of palatal implants (SB group) within 72 hours of insertion.
Study: 18797833
Drug: Conventional loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional loading of palatal implants (KB group) after a 12-week healing period.
Study: 15844302
Drug: Intrapericardial urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapericardial urokinase along with conventional treatment
Study: 15844302
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone (including pericardiocentesis and drainage)
Study: 12051573
Drug: Nitazoxanide (N)
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide (N) 1 g
Study: 12051573
Drug: Nitazoxanide (N)
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide (N) 2 g
Study: 12051573
Drug: Nitazoxanide (N)
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide (N) 3 g
Study: 12051573
Drug: Nitazoxanide (N)
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide (N) 4 g
Study: 10082778
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium diet (4.67 g/L)
Study: 10082778
Drug: Normal calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal calcium diet (2.0 g/L)
Study: 10082778
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium diet (4.67 g/L) and Normal calcium diet (2.0 g/L)
Study: 30840961
Drug: Intermittent-full-standard-dose tamsulosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent-full-standard-dose tamsulosin
Study: 30840961
Drug: Low-dose tamsulosin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tamsulosin
Study: 30840961
Drug: Full-standard-dose tamsulosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-standard-dose tamsulosin (Control)
Study: 28627980
Drug: Multi-intervention group
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-intervention group (specialist-based, lifestyle modification and pharmacological treatment)
Study: 26402011
Drug: ST101 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST101 (10, 60, or 120 mg QD)
Study: 26402011
Drug: ST101 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST101 (120 mg QD)
Study: 19553296
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (5 mg/d for infants aged 2 wk to 6 mo; 10 mg/d for infants aged >6 mo)
Study: 16892419
Drug: Paroxetine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (maximum 60 mg by week 7)
Study: 11289332
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled budesonide (1,600 microg daily)
Study: 11289332
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (1 mg/kg daily) plus medium-dose inhaled budesonide (800 microg daily)
Study: 10557952
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled budesonide
Study: 11289332
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone plus medium-dose inhaled budesonide
Study: 2647896
Drug: Controlled-release oral
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release oral morphine sulfate (MSC) dosed at 8-, 10-, and 12-hour intervals
Study: 2647896
Drug: Immediate-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release morphine sulfate (IRMS) dosed every four hours
Study: 2647896
Drug: Prestudy analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prestudy analgesics
Study: 26177074
Drug: Indacaterol/Glycopyrrolate (27.5/15.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/Glycopyrrolate (27.5/15.6 μg twice daily)
Study: 26177074
Drug: Indacaterol (27.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol (27.5 μg twice daily)
Study: 26177074
Drug: Glycopyrrolate (15.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (15.6 μg twice daily)
Study: 16875154
Drug: Doxazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (2 mg daily for 12 months)
Study: 12947128
Drug: 570 kcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 570 kcal carbohydrate rich supplement
Study: 8668288
Drug: Piroxicam cinnamate
Normalized name: piroxicam cinnamate
DrugBank: Piroxicam cinnamate (DB15883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam cinnamate 30 mg tablets (Sinartrol), 1 tablet twice daily for 2 days followed by 1 tablet daily for 13 days
Study: 8668288
Drug: Piroxicam cinnamate
Normalized name: piroxicam cinnamate
DrugBank: Piroxicam cinnamate (DB15883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam cinnamate 20 mg tablets, 1 tablet twice daily for 2 days followed by 1 tablet daily for 13 days
Study: 2053016
Drug: Ivermectin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (150 to 220 mcg/kg, five single oral doses, one every six months)